ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	JPRN
Last refreshed on:	17 October 2023
Main ID:	JPRN-UMIN000022151
Date of registration:	30/04/2016
Prospective Registration:	Yes
Primary sponsor:	Department of Neurology, Shimane University Hospital
Public title:	The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy
Scientific title:	The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy
Date of first enrolment:	2016/04/30
Target sample size:	5
Recruitment status:	Complete: follow-up complete
URL:	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025527
Study type:	Interventional
Study design:	Single arm Non-randomized
Phase:	Not selected

Countries of recruitment
Japan

Contacts

Name:	Chizuko Hamada
Address:	89-1, Enya, Izumo, Shimane, 693-8501, japan Japan
Telephone:	0853-20-2195
Email:	okuzihc.@med.shimane-u.ac.jp
Affiliation:	Shimane University Hospital Department of Neurology

Name:	Chizuko Hamada
Address:	89-1, Enya, Izumo, Shimane, 693-8501, japan Japan
Telephone:	0853-20-2195
Email:	okuzihc.@med.shimane-u.ac.jp
Affiliation:	Shimane University Hospital Department of Neurology

Key inclusion & exclusion criteria

Inclusion criteria:
Exclusion criteria: 1) Patients with other infection of the central nervous system. 2) Physical status is severe or unstable. 3) Patients with severe psychiatric disorder. 4) Pregnant women or patients with possible pregnancy. 5) Patients with a history of hypersensitivity to this drug.

Age minimum: 20years-old
Age maximum: Not applicable
Gender: Male and Female

Health Condition(s) or Problem(s) studied

The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy

Intervention(s)

mefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manths

Primary Outcome(s)

Survival time and an improvement in KPS and MMSE at baseline and 6 months thereafter.

Secondary Outcome(s)

Secondary ID(s)

Source(s) of Monetary Support

Ministry of Health, Labour and Welfare

Secondary Sponsor(s)

Ethics review

Status: YES
Approval date: 24/12/2018
Contact:

Results

Results available:	Yes
Date Posted:
Date Completed:	24/12/2018
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.